Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 15 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 11396544

    Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted

  2. US 11390682

    Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted

  3. US 11390683

    Anti-mesothelin polypeptides and proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted

  4. US 11384153

    Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted

  5. US 11377502

    Anti-MSR1 antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted

  6. US 11377491

    Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

    The Board of Regents of the University of Texas System · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted

  7. US 11376318

    Methods of preparing anti-human papillomavirus antigen t cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted

  8. US 11370828

    Anti-coronavirus antibodies and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Svcs. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted

  9. US 11370832

    Anti-Tau antibodies and methods of use thereof

    DENALI THERAPEUTICS INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted

  10. US 11365265

    Anti-C5 antibody combinations and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted

  11. US 11359024

    Anti-AVB8 antibodies and compositions and uses thereof

    The Regents of the University of California · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted

  12. US 11352410

    Anti-KK-LC-1 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted

  13. US 11352435

    Anti-CD133 monoclonal antibodies and related compositions and methods

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted

  14. US 11351185

    Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted

  15. US 11338032

    Methods of preparing anti-human papillomavirus antigen T cells

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted May 24, 2022 · Expires May 19, 2042

    granted

  16. US 11331385

    Methods of preparing anti-human papillomavirus antigen T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 17, 2022 · Expires May 12, 2042

    granted

  17. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  18. US 11318211

    Dosage regimes for the administration of an anti-CD19 ADC

    ADC THERAPEUTICS SA · Granted May 3, 2022 · Expires Apr 28, 2042

    granted

  19. US 11311517

    Combination of small molecule CD-47 inhibitors with other anti-cancer agents

    Aurigene Discovery Technologies Limited · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted

  20. US 11313868

    Methods of detecting anti-folic acid antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted

  21. US 11306135

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  22. US 11304935

    Use of I-BRD9 or derivatives thereof in preparing anti-epileptic drugs

    University of South China · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  23. US 11306155

    Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  24. US 11306148

    Anti-NPR1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.